Darolutamide (ODM-201) for the treatment of prostate cancer

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

(2017) Nicolas Mottet et al.   EUROPEAN UROLOGY

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

(2016) Matthew R. Smith et al.   EUROPEAN UROLOGY

Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study

(2016) Christophe Massard et al.   EUROPEAN UROLOGY

Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer

(2016) Kristine M Wadosky et al.   International Journal of Biological Sciences

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy.

(2016) Karim Fizazi et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) C. Parker et al.   ANNALS OF ONCOLOGY

Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials

(2015) Robert J. van Soest et al.   BMC Medicine

Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance

(2015) DJ Crona et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The 2014 CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC)

(2015) Fred Saad et al.   CUAJ-Canadian Urological Association Journal

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

(2015) Karim Fizazi et al.   Expert Review of Anticancer Therapy

Castration-Resistant Prostate Cancer: AUA Guideline Amendment

(2015) Michael S. Cookson et al.   JOURNAL OF UROLOGY

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

(2015) Charles J Ryan et al.   LANCET ONCOLOGY

Therapy escape mechanisms in the malignant prostate

(2015) Frédéric R. Santer et al.   SEMINARS IN CANCER BIOLOGY

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies

(2015) Anu-Maarit Moilanen et al.   Scientific Reports

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

(2014) Karim Fizazi et al.   LANCET ONCOLOGY

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

(2014) Tomasz M. Beer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY